UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mutations and prognosis in primary myelofibrosis

Leukemia, 2013-09, Vol.27 (9), p.1861-1869

2013

Volltextzugriff (PDF)

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

Leukemia, 2016-02, Vol.30 (2), p.431-438

2016

Volltextzugriff (PDF)

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

Leukemia, 2008-05, Vol.22 (5), p.905-914

2008

Volltextzugriff (PDF)

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

Leukemia, 2015-11, Vol.29 (11), p.2126-2133

2015

Volltextzugriff (PDF)

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

Leukemia, 2016-05, Vol.30 (5), p.1018-1024

2016

Volltextzugriff (PDF)

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Leukemia, 2014-09, Vol.28 (9), p.1804-1810

2014

Volltextzugriff (PDF)

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

Leukemia, 2014-02, Vol.28 (2), p.449-451

2014

Volltextzugriff (PDF)

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Leukemia, 2008-02, Vol.22 (2), p.437-438

2008

Volltextzugriff (PDF)

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

Leukemia, 2013-05, Vol.27 (5), p.997-999

2013

Volltextzugriff (PDF)

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

Haematologica (Roma), 2011-02, Vol.96 (2), p.315-318

2011

Volltextzugriff (PDF)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Leukemia, 2017-04, Vol.31 (4), p.896-902

2017

Volltextzugriff (PDF)

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

Leukemia, 2017-04, Vol.31 (4), p.882-888

2017

Volltextzugriff (PDF)

How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Leukemia, 2016-07, Vol.30 (7), p.1453-1455

2016

Volltextzugriff (PDF)

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

Haematologica (Roma), 2013-09, Vol.98 (9), p.1344-1352

2013

Volltextzugriff (PDF)

Strategies for dissemination and implementation of guidelines

Neurological sciences, 2006-06, Vol.27 Suppl 3 (S3), p.S231-s234

Barosi, G

2006

Volltextzugriff (PDF)

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Leukemia, 2013-10, Vol.27 (10), p.2084-2086

2013

Volltextzugriff (PDF)

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis

Leukemia, 2015-03, Vol.29 (3), p.740-740

2015

Volltextzugriff (PDF)

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Leukemia, 2015-05, Vol.29 (5), p.1209-1210

2015

Volltextzugriff (PDF)

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Leukemia, 2014-11, Vol.28 (11), p.2267-2270

2014

Volltextzugriff (PDF)

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

Bone marrow transplantation (Basingstoke), 2010-03, Vol.45 (3), p.458-463

2010

Volltextzugriff (PDF)

SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias

Annals of oncology, 2014-12, Vol.25 (12), p.2339-2350

2014

Volltextzugriff (PDF)

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

Leukemia research, 2010-12, Vol.34 (12), p.1576-1588

2010

Volltextzugriff (PDF)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Leukemia, 2017-05, Vol.31 (5), p.1252-1252

2017

Volltextzugriff (PDF)

Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

Leukemia, 2012-05, Vol.26 (5), p.1148-1149

2012

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(263)
Mit Volltextzugriff
(188)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(201)
Science & Technology
(176)
Life Sciences & Biomedicine
(161)
Hematology
(131)
Male
(101)
Female
(96)
Biological And Medical Sciences
(93)
Medical Sciences
(91)
Middle Aged
(86)
Adult
(85)
Aged
(68)
Hematologic And Hematopoietic Diseases
(52)
Oncology
(43)
Adolescent
(35)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(34)
Erythropoiesis
(28)
Myelofibrosis
(27)
Child
(24)
Primary Myelofibrosis - Complications
(23)
Primary Myelofibrosis - Pathology
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mutations and prognosis in primary myelofibrosis

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations

How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis?

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups

Strategies for dissemination and implementation of guidelines

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias

Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines

Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

Aktive Filter

Suchergebnisse filtern